| Trial ID: | L0742 |
| Source ID: | NCT02738905
|
| Associated Drug: |
Rifaximin
|
| Title: |
Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Rifaximin
|
| Outcome Measures: |
Primary: Change in serum TMAO levels, Change from Baseline to Day 7 | Secondary: Change in serum TMAO levels, Change from Baseline to Day 21|Change in fecal bacterial species, Change from Baseline to Day 7|Change in fecal bacterial colony numbers, Change from Baseline to Day 7|Change in fecal bacterial species, Change from Baseline to Day 21|Change in fecal bacterial colony numbers, Change from Baseline to Day 21
|
| Sponsor/Collaborators: |
Sponsor: Jason Stubbs, MD | Collaborators: American Heart Association
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-01
|
| Completion Date: |
2019-02-26
|
| Results First Posted: |
|
| Last Update Posted: |
2019-02-28
|
| Locations: |
University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Westwood Dialysis Center, Westwood, Kansas, 66205, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02738905
|
